Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
In the pivotal phase 3 CELESTIAL trial, CABOMETYX provided a statistically significant and clinically meaningful improvement versus placebo in overall survival (OS)